Results from the phase 2 Daro-PET study (NCT05900973) showed that prostate-specific membrane antigen (PSMA) expression was boosted with short-course darolutamide (Nubeqa) in patients with high-risk ...

Early trials of the drug VIR-5500 showed it shrinking tumours in some patients ...

The new drug uses a so-called cloaking device and only activates when it reaches the tumour ...

The new drug, known as VIR-5500, uses a so-called cloaking device and only activates when it reaches the tumour ...

When most people think about cancer treatment, they picture chemotherapy, grueling surgeries, harsh drug regimens, and devastating side effects. Medicus ...

A drug for advanced prostate cancer has shown “remarkable” results in an early-stage trial, with patients who had previously stopped being receptive to treatment finding their tumours shrinking, ...

The Prostate Cancer Foundation (PCF) today announced a $10 million unrestricted gift from an anonymous donor to launch a TACTICAL (Therapy ACceleration To Intercept CAncer Lethality) Award, which will ...

In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate ...

FG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen receptor pathway inhibitor (ARPI)-treated, ...

So far, in a Phase I trial, incidents of CRS have been low grade on VIR-5500, and 14 of 17 evaluable patients saw more than a 50 percent decrease in PSA levels.